Kraft Heinz pulling certain artificial dyes from its US products in 2027
The move comes nearly two months after U.S. health officials said that they would urge foodmakers to phase out petroleum-based artificial colors in the nation's food supply.
Kraft Heinz said Tuesday that almost 90% of its U.S. products already don't contain food, drug & cosmetic colors, but that the products that do still use the dyes will have them removed by the end of 2027. FD&C colors are synthetic additives that are approved by the U.S. Food and Drug Administration for use in food, drugs and cosmetics.
The company said that it will instead use natural colors for the products.
'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio," Pedro Navio, North America President at Kraft Heinz, said in a statement.
Kraft Heinz stripped artificial colors, flavors and preservatives from its macaroni and cheese in 2016 and said it has never used artificial dyes in its ketchup.
The company plans to work with licensees of its brands to encourage them to remove the dyes.
In April Food and Drug Administration Commissioner Marty Makary said at a news conference that the agency would take steps to eliminate the synthetic dyes by the end of 2026, largely by relying on voluntary efforts from the food industry.
Health advocates have long called for the removal of artificial dyes from foods, citing mixed studies indicating they can cause neurobehavioral problems, including hyperactivity and attention issues, in some children. The FDA has maintained that the approved dyes are safe and that 'the totality of scientific evidence shows that most children have no adverse effects when consuming foods containing color additives.'
The FDA currently allows 36 food color additives, including eight synthetic dyes. In January, the agency announced that the dye known as Red 3 — used in candies, cakes and some medications — would be banned in food by 2027 because it caused cancer in laboratory rats.
Artificial dyes are used widely in U.S. foods. In Canada and in Europe — where synthetic colors are required to carry warning labels — manufacturers mostly use natural substitutes. Several states, including California and West Virginia, have passed laws restricting the use of artificial colors in foods.
Many U.S. food companies are already reformulating their foods, according to Sensient Colors, one of the world's largest producers of food dyes and flavorings. In place of synthetic dyes, foodmakers can use natural hues made from beets, algae and crushed insects and pigments from purple sweet potatoes, radishes and red cabbage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
38 minutes ago
- Globe and Mail
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational, and oral orexin 2 receptor agonist, alixorexton (formerly ALKS 2680), for treating patients with narcolepsy type 1 (NT1). In the Vibrance-1 study, patients were randomized to receive alixorexton (4 mg, 6 mg or 8 mg) or placebo to be taken once daily for six weeks. Data from the study showed that treatment with alixorexton across all doses led to a statistically significant, clinically meaningful and dose-dependent improvement from baseline versus placebo in wakefulness on the Maintenance of Wakefulness Test (MWT) — the study's primary endpoint. Treatment with alixorexton across all doses demonstrated statistically significant and clinically meaningful improvements from baseline in excessive daytime sleepiness versus placebo at week six on the Epworth Sleepiness Scale — a key secondary endpoint of the Vibrance-1 study. Although all three doses of alixorexton led to improvements in weekly cataplexy rates — also a key secondary endpoint of the study — only the 6 mg dose achieved statistical significance. This might have hurt investor sentiment and caused the stock to decline 8.8% yesterday. Also, treatment with once-daily alixorexton led to robust and clinically meaningful improvements in patient-reported outcomes for excessive daytime sleepiness, fatigue and cognition compared to placebo. Treatment with alixorexton across all doses was generally safe and well-tolerated. ALKS' Price Performance Shares of Alkermes have declined 7.3% so far this year compared with the industry 's decrease of 2.2%. Building on the overall success of the Vibrance-1 study, management is planning to initiate a global phase III program for alixorexton in patients with NT1. NT1 is a chronic sleep disorder causing excessive daytime sleepiness and sudden muscle weakness called cataplexy due to orexin deficiency. We note that orexin agonists like alixorexton directly target the brain's orexin system — the root cause of NT1. Unlike other available drugs that only fight sleepiness, orexin agonists may also prevent cataplexy, offering a more natural and complete treatment approach. This can make them a promising and transformative treatment in narcolepsy care. The detailed safety and efficacy data from the phase II Vibrance-1 study are expected to be presented at an upcoming scientific conference. ALKS' Other Development Activities With Alixorexton Besides NT1, alixorexton is also being studied for the treatment of narcolepsy type 2 ('NT2') and idiopathic hypersomnia ('IH'). The phase II Vibrance-2 study is evaluating the safety and efficacy of alixorexton versus placebo in adults with NT2. Enrollment in this study is expected to be completed shortly, with data from the same expected during fall. In April 2025, the company initiated the phase II Vibrance-3 study, evaluating the safety and efficacy of alixorexton in adults with idiopathic hypersomnia, a rare, chronic and neurological sleep disorder. Per management, if successfully developed and upon potential approval, alixorexton can serve an area of high unmet medical need in the treatment of NT1 and NT2 as well as IH. However, upon potential approval, alixorexton is likely to face competition from Axsome 's AXSM Sunosi (solriamfetol), which is presently marketed in the United States for the treatment of narcolepsy. Several label expansion studies on solriamfetol are also currently underway. Axsome acquired the U.S. rights for Sunosi from Jazz Pharmaceuticals JAZZ in May 2022. AXSM began selling Sunosi in the U.S. market in May 2022. JAZZ received approval for Sunosi as a treatment for narcolepsy in 2019. Jazz's other sleep disorder drugs, Xyrem and Xywav, also hold a strong market share. ALKS' Zacks Rank & Stock to Consider Alkermes currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Arvinas ARVN, sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, estimates for Arvinas' 2025 loss per share have narrowed from $1.60 to $1.51. Loss per share estimates for 2026 have narrowed from $3.28 to $2.98 during the same period. ARVN stock has plunged 60.7% year to date. Arvinas' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM): Free Stock Analysis Report Arvinas, Inc. (ARVN): Free Stock Analysis Report
Calgary Herald
an hour ago
- Calgary Herald
Joe Biden's 'absolutely horrible debate' against Donald Trump due to Ambien, son Hunter says
Article content In the days following a disastrous debate against Donald Trump in the first U.S. presidential debate last summer, then-president Joe Biden eventually blamed fatigue for his poor showing that night. Article content His son Hunter, in a rare one-on-one interview posted this week, said there was good reason for his father's fatigue in the 'absolutely horrible debate': staff had given the president a sleeping pill. Article content Article content Article content 'And it feeds into every bulls— story that anybody wants to tell.' Article content Article content The prescription drug is predominantly used to treat insomnia by helping people fall asleep faster and sleep for longer. According to the FDA, common risks for older adults can include confusion and memory problems, as well as next-day drowsiness. Article content Biden later clarified to ABC that he was not implying his father was given Ambien directly before the debate and had 'no idea whether or not he used Ambien while travelling through multiple times zones in the weeks leading up to the debate.' Article content Article content 'My point was that his debate performance was completely out of character then and now,' he said. Article content Article content Prior to a week of debate prep spent at Camp David between June 20-27, Joe Biden had travelled to France to commemorate the 80th anniversary of D-Day on June 6, then back to the U.S. to continue his campaign, according to NBC. He returned to Europe for the Group of Seven meeting on June 14 and was back in Los Angeles for a fundraiser on June 15 — 12 days prior to the tête-à-tête with Trump.
Edmonton Journal
2 hours ago
- Edmonton Journal
Joe Biden's 'absolutely horrible debate' against Donald Trump due to Ambien, son Hunter says
Article content In the days following a disastrous debate against Donald Trump in the first U.S. presidential debate last summer, then-president Joe Biden eventually blamed fatigue for his poor showing that night. Article content His son Hunter, in a rare one-on-one interview posted this week, said there was good reason for his father's fatigue in the 'absolutely horrible debate': staff had given the president a sleeping pill. Article content Article content Article content Article content The prescription drug is predominantly used to treat insomnia by helping people fall asleep faster and sleep for longer. According to the FDA, common risks for older adults can include confusion and memory problems, as well as next-day drowsiness. Article content Biden later clarified to ABC that he was not implying his father was given Ambien directly before the debate and had 'no idea whether or not he used Ambien while travelling through multiple times zones in the weeks leading up to the debate.' Article content Article content 'My point was that his debate performance was completely out of character then and now,' he said. Article content Article content Prior to a week of debate prep spent at Camp David between June 20-27, Joe Biden had travelled to France to commemorate the 80th anniversary of D-Day on June 6, then back to the U.S. to continue his campaign, according to NBC. He returned to Europe for the Group of Seven meeting on June 14 and was back in Los Angeles for a fundraiser on June 15 — 12 days prior to the tête-à-tête with Trump.
